<DOC>
	<DOCNO>NCT01159847</DOCNO>
	<brief_summary>The aim study investigate protective effect sitagliptin β cell function patient adult-onset latent autoimmune diabetes ( LADA ) mechanism .</brief_summary>
	<brief_title>Protective Effects Sitagliptin β Cell Function Patients With Adult-onset Latent Autoimmune Diabetes ( LADA )</brief_title>
	<detailed_description>Adult-onset latent autoimmune diabetes ( LADA ) , etiologically belong type 1 diabetes ( T1D ) , characterize presence islet autoantibody , islet cell antibody ( ICA ) glutamic acid decarboxylase antibody ( GADA ) , prones develop β-cell failure . The goal treatment LADA suppression autoimmune β cell destruction , preservation islet function prevention diabetic complication . Recently two class compound approved FDA T2D therapeutic : glucagon-like peptide-1 ( GLP-1 ) receptor agonist ( incretin mimetic ) exenatide ( Byetta ) dipeptidyl peptidase IV ( DPP-IV ) inhibitor sitagliptin ( Januvia ) vildagliptin ( Galvus ) . They show reduce HbA1c , fast glucose improve β cell function T2D patient , mono-therapy combination metformin thizolidinediones . Besides , vitro study show incretin-based therapy stimulate β-cell proliferation survival , increase β cell insulin content inhibit apoptosis . Moreover , several short-term pilot study suggest GLP-1 may also potential treat T1D . Several finding suggest Ex-4 may also act regulator immune response addition potential effect β cell proliferation . Therefore , hypothesize DPP-IV inhibitor might provide therapeutic advantage T1D though study report . Besides β cell function , another important target insulin sensitivity . As DPP-IV inhibitor , clinical trial demonstrate beneficial effect insulin sensitivity subject T2D IFG indiabetic rat model . We 'd like explore possible effect sitagliptin insulin sensitivity LADA patient HOMA-IR index euglycemic clamp technique . In addition , systemic inflammation associate wide array plasma proteins pro-inflammatory cytokine ( i.e. , CRP , TNF-α , IL-6 ) play additional role pathogenesis insulin resistance diabetes . It interest investigate adipokines proinflammmatory cytokine sitagliptin therapy study . Hence , aim explore effect sitagliptin plus insulin β cell function , insulin sensitivity , pro-inflammatory cytokine immune regulation include Teff Treg frequency , function patient LADA .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Diabetes diagnose accord report WHO 1999 . 2 . Age onset 25~70 year . 3 . Disease duration less 3 year . 4 . No ketoacidosis within first 6 month diagnosis diabetes . 5 . GADA positive twice within one month . 6 . FCP level 0.2 nmol/L . 1 . Insulin requirement 0.8 units/kg/day . 2 . Evidence chronic infection acute infection affect blood glucose control within 4 week prior visit 1 . 3 . History malignancy . 4 . Pregnancy , breastfeed plan pregnancy within two year . 5 . Secondary diabetes . 6 . Congestive heart failure require pharmacologic treatment . 7 . Renal disease renal dysfunction diabetic nephropathy suggest serum creatinine levels≥1.5 mg/dL ( 132μmol/L ) male ≥1.4mg/dL ( 123μmol/L ) female abnormal creatinine clearance Visit 1 . 8 . Concurrent medical condition may interfere interpretation efficacy safety data study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>sitagliptin</keyword>
	<keyword>LADA</keyword>
	<keyword>C-Peptide</keyword>
	<keyword>Flow Cytometry</keyword>
	<keyword>ELISPOT</keyword>
</DOC>